Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’
We recently published an article titled Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus. In this article, we are going ...
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to ...
Why Recursion Pharmaceuticals Stock Is Sinking Today
Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering
Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...
Cathie Wood Capitalizes on Pullback in Tempus AI to Buy Additional Stock Worth $14.4M
Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...
Spotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options Activity
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and ...
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...
Nasdaq28d
Interesting RXRX Call Options For April 4th
The call contract at the $8.50 strike price has a current bid of 30 cents. If an investor was to purchase shares of RXRX stock at the current price level of $8.28/share, and then sell-to-open that ...